Ipilimumab for metastatic melanoma
| Author : Pierre Allain
||Date : 2010-10-25
Ipilimumab is a human type monoclonal antibody which blocks the cytotoxic T- lymphocytes-associated antigen 4, CTLA-4, it is anti-CTLA-4.
According to a clinical trial published in the NEJM ipilimumab prolongs survival of patients with metastatic melanoma of 4 months, survival spending from 6 months to 10 months, but at the cost of significant adverse effects.